SAFECODE DRUG TECHNOLOGIES CORP.

Basic loss per share is computed by dividing the net loss attributable to the common stockholders by the weighted average number of shares of common stock outstanding during the period. Fully diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Common stock equivalents were not included in the computation of diluted earnings per share in the statement of operations due to the fact that the Company reported a net loss and to do so would be anti-dilutive for the periods presented.

On November 5, 2012, the Company signed a $32,500 convertible promissory note with a third party.  The note bears interest at 8% per annum and is due on August 5, 2013.  The note has conversion rights that allow the holder of the note to convert after 180 days all or any part of the remaining principal balance into the Company’s common stock at a price equal to 45% of the average of the lowest two trading prices for the Common Stock during the most recent twenty day period. The Company issued 15,791,803shares of common stock in payment of $31,500 against the balance of this note. As of June 30, 2013, the remaining balance of this loan was $1,000.

As of June 30, 2013, loans to related parties amounted to $437. The loans are unsecured, non-interest bearing, and due on demand.

From January 1, 2013 to June 30, 2013, the Company issued 15,791,803 shares of its common stock valued at $31,500 to retire convertible debt.